<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885218</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1209-302</org_study_id>
    <nct_id>NCT04885218</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia and Hyperlipidemia</brief_title>
  <official_title>A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in the Stable Treatment of Patients With Hypercholesterolemia and Hyperlipidemia .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SHR-1209&#xD;
      subcutaneous administration in patients with hypercholesterolemia and hyperlipidemia after&#xD;
      lipid-lowering therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR-1209 combined with lipid-lowering agents</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in LDL-C relative to baseline</measure>
    <time_frame>at 24 weeks of treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The value of changes in LDL-C relative to baseline</measure>
    <time_frame>at 24 weeks of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure with the unit of mm Hg</measure>
    <time_frame>through study completion, an average of 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body temperature with the unit of °C</measure>
    <time_frame>through study completion, an average of 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse rate with the unit of beats per minute</measure>
    <time_frame>through study completion, an average of 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathe with the unit of beats per minunt</measure>
    <time_frame>through study completion, an average of 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>through study completion, an average of 56 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>injection reactions, the investigators through check up the skin of abdomen</measure>
    <time_frame>through study completion, an average of 56 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">675</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1：SHR-1209 / placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2：SHR-1209 /placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3：SHR-1209 / placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1209 ;placebo</intervention_name>
    <description>SHR-1209/placebo high dose</description>
    <arm_group_label>Cohort 1：SHR-1209 / placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1209 ;placebo</intervention_name>
    <description>SHR-1209/placebo medium dose</description>
    <arm_group_label>Cohort 2：SHR-1209 /placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1209 ;placebo</intervention_name>
    <description>SHR-1209/placebo low dose</description>
    <arm_group_label>Cohort 3：SHR-1209 / placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 and ≤80 on the date of signing the informed consent, male or female;&#xD;
&#xD;
          2. The report of LDL-C should be higher than the ideal lipid-lowering target according to&#xD;
             ASCVD history;&#xD;
&#xD;
          3. Understand the study procedures and methods, volunteer to participate in the study,&#xD;
             and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have the following diseases or treatment history :(1) Have known allergic reaction to&#xD;
             experimental drugs, or have severe allergic reaction to other antibody drugs;(2)&#xD;
             previous diagnosis of familial hypercholesterolemia according to Simon Broome&#xD;
             Criteria;(3) cardiac function as defined by the New York Heart Association (NYHA)&#xD;
             grade III-IV at screening or randomization or latest detected LVEF&lt;30%;&#xD;
&#xD;
          2. Any of the laboratory indicators met the following criteria at screening or at&#xD;
             randomization :(1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&#xD;
             exceeding 3 times the upper limit of normal (ULN), or total bilirubin exceeding 2&#xD;
             times the upper limit of normal (ULN);(2) Creatine kinase (CK) exceeds 3 times the&#xD;
             upper limit of normal value (ULN);&#xD;
&#xD;
          3. General conditions :(1) the investigator judged that subcutaneous injection was not&#xD;
             appropriate;(2) Fertile female subjects who did not use contraception within 4 weeks&#xD;
             before screening; Or male or female subjects who do not agree to use high-efficiency&#xD;
             contraceptives during the trial and for 24 weeks after the last dosing;(3) Women who&#xD;
             are pregnant or lactating.&#xD;
&#xD;
          4. The Investigator determines that the subjects have poor compliance or have any factors&#xD;
             that may prevent them from participating in the study, including, but not limited to,&#xD;
             the study placing the subjects at unacceptable risk or possibly interfering with the&#xD;
             study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miaomiao Shi</last_name>
    <phone>+8618036617171</phone>
    <email>miaomiao.shi@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shimin An</last_name>
    <phone>+8618612511707,</phone>
    <email>shimin.an@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

